JAK1 and neoplasm: Genetic analysis of tumors from patients with melanoma and colon cancer who did not respond to PD1 blockade therapy despite their high mutation burden and high percentage of pre-existing tumor specific T cells, were identified to acquire loss of function mutations in JAK1/2 kinases and decreased MHCI surface expression [102,104].